BioStock Investor Pitch: Alzinova
Date: 2026-02-11
Alzinova’s CEO Tord Labuda recently joined BioStock’s studio to present the Company’s path forward, including preparations for the planned Phase II study with ALZ-101 and the ongoing rights issue.
The rights issue, running between February 6–20, is intended to strengthen the Company’s financial position and support critical CMC and regulatory preparations ahead of the next clinical phase, while maintaining momentum in partner discussions.
For a complete overview of the rights issue, including the prospectus, latest interviews and related materials, please visit our dedicated information page
Marketing communication. The offer to subscribe for units in Alzinova is made solely through the prospectus published on February 3, 2026, which is available on Alzinova’s issue page